Extra-adrenal paragangliomas (PGLs) are rare tumours that develop from neuroendocrine cells derived from the neural crest. They may arise anywhere along the paraganglion system and can be associated with the sympathetic or the parasympathetic nervous system. Extra-adrenal PGLs of the sympathetic chains usually cause symptoms of catecholamine over-secretion. Conversely, parasympathetic head and neck (H&N) and thoracic PGLs are almost always non-secreting tumours which are discovered on imaging studies or revealed by symptoms of compression or infiltration of the adjacent structures [1] .
PGLs are characterized by a high frequency of hereditary forms with a propensity for multifocal disease. A specific correlation between the gene involved and tumour location has been reported [1] . Most often, extra-adrenal PGLs are benign and progress slowly. The rate of distant spread is wide, depending on tumour location, size and genetic background [1] .
In extra-adrenal PGLs, pretreatment imaging including nuclear medicine techniques is crucial for providing accurate staging as well as in identifying multifocal or metastatic disease. Recent European Association of Nuclear Medicine (EANM) guidelines for nuclear medicine imaging of PGLs provided a practical algorithm for selecting the most appropriate imaging procedure based on a tailored approach, taking into account genetic mutation, location of the PGL and presence of metastases, starting from the assumption that there is no 'gold standard' imaging technique for all patients with extra-adrenal PGL [1] [2] [3] . 18 F-DOPA positron emission tomography (PET)/CT is suggested as first-line imaging method in H&N and abdominal non-metastatic extra-adrenal PGLs; this method may be useful in metastatic PGLs in the absence of succinate dehydrogenase B (SDHB) gene mutations or when genetic status is unknown [1, 4] . F-Fluorodeoxyglucose (FDG) PET/CT is especially sensitive in the setting of SDH-and von Hippel-Lindau disease (VHL)-related sympathetic extra-adrenal PGLs and it seems to be the imaging modality of choice for SDHB-related metastatic PGLs; this method may also provide useful prognostic information.
18 F-Fluorodopamine and 11 Chydroxyephedrine PET are both accurate methods in evaluating patients with extra-adrenal and metastatic PGL but, to date, these techniques have limited availability [1] . The diagnostic performance of PET or PET/CT with various radiopharmaceuticals is clearly superior to that of radioiodinated metaiodobenzylguanidine (MIBG) scintigraphy in patients with extra-adrenal and metastatic PGL; however, MIBG scintigraphy maintains a unique role in selecting patients suitable for 131 I-MIBG therapy [5] . Somatostatin receptor PET/CT is increasingly used in patients with known or suspected neuroendocrine tumours demonstrating high diagnostic accuracy and is superior compared to 111 In-pentetreotide scintigraphy in this setting [6, 7] . Recent articles in the literature assessed the diagnostic accuracy of somatostatin receptor PET/CT using different somatostatin analogues labelled with 68 Ga ( 68 Ga-DOTATATE, 68 Ga-DOTANOC and 68 Ga-DOTATOC) in patients with extraadrenal PGL [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , based on the increased expression of somatostatin receptors in PGL neoplastic cells [18] .
The diagnostic performance of 68 Ga-DOTATATE PET/CT in patients with PGL was recently evaluated by Maurice et al. in a retrospective study including nine patients with extra-adrenal PGL (six H&N, two abdominal and one thoracic PGL).
68
Ga-DOTATATE PET/CT detected more lesions compared to 123 I-MIBG scintigraphy and conventional imaging mainly in H&N and metastatic PGLs [8] , confirming previous results of the same group in a more limited population of extra-adrenal PGL [9] . About 68 Ga-DOTANOC PET/CT, in 2008, Fanti et al. described the usefulness of this method in detecting neuroendocrine tumours located in unusual sites, including patients with extra-adrenal PGL [10] , and these findings were confirmed in a recent article including some cases of extra-adrenal PGL [11] . In 2012, a prospective study of Naswa et al. demonstrated the higher diagnostic accuracy of Ga-DOTANOC PET/CT: 17 were H&N PGLs, while the rest were detected in the mediastinum, abdomen and urinary bladder [12] . A recent retrospective study of Sharma et al. evaluated 26 patients with H&N PGL by using 68 Ga-DOTANOC PET/CT. This imaging method was positive in all 26 patients being very useful for the baseline evaluation of patients with H&N PGL and demonstrating synchronous PGLs at other sites and distant metastases with superior diagnostic accuracy compared to 131 I-MIBG scintigraphy and conventional imaging [13] , confirming the preliminary results of the same group reported in a pilot study about 68 Ga-DOTANOC PET/CT on 5 H&N PGLs [14] . About 68 Ga-DOTATOC, the group in Innsbruck previously reported the uptake of this radiopharmaceutical in some cases of extra-adrenal PGL [15, 16] .
Due to the encouraging results obtained with somatostatin receptor PET/CT in the evaluation of extra-adrenal PGLs, a head-to-head comparison of 68 Ga-somatostatin analogues with other PET radiopharmaceuticals would be very useful in this setting [17] .
In their retrospective study Kroiss Ga-DOTATOC PET showed lesions that were not detected by CT. These authors conclude that 68 Ga-DOTATOC PET may be superior to 18 F-DOPA PET and to diagnostic CT in staging of extra-adrenal PGL, particularly in metastatic or multifocal disease [19] . Ga-somatostatin analogues and other PET tracers in this setting should take into account the genetic status of patients with extra-adrenal PGL. Beyond the diagnostic accuracy, an undoubted advantage of somatostatin receptor PET compared to other PET tracers is the ability to select patients potentially eligible for peptide radioreceptor therapy, which a preliminary study has described as feasible for patients with extra-adrenal PGL representing a good alternative treatment when surgical or radiation therapy are contraindicated [20] .
In the current era of a growing number of available PET tracers, PGL imaging has moved beyond tumour localization towards functional characterization of tumours [3] . Therefore, it is important to compare PET radiopharmaceuticals with different uptake mechanisms not only to establish a superior diagnostic performance of a specific radiopharmaceutical but also to evaluate matched or mismatched findings, to identify possible advantages of a multidisciplinary approach or to obtain prognostic information [2] . The use of different PET radiopharmaceuticals in the same patient may be particularly useful in cases of extra-adrenal PGL; anyway, this strategy needs to be validated by specific cost-effective analyses for its introduction into clinical practice.
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